Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) show promise in cancer treatment. This study found that 18F-fluorthanatrace (18F-FTT) uptake in breast cancer correlates with PARP-1 protein expression, suggesting its potential as a biomarker for PARPi therapy.
Area Of Science
- Oncology
- Radiochemistry
- Biomarker Development
Background
- Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) are effective in treating various cancers, but predicting patient response remains a challenge.
- Current biomarkers for PARPi therapy do not consistently identify patients who will benefit.
- 18F-fluorthanatrace (18F-FTT), a PARPi analog, is being investigated as a potential imaging biomarker for PARPi response.
Purpose Of The Study
- To characterize the pharmacokinetics of 18F-FTT in breast cancer patients.
- To optimize imaging timing for 18F-FTT in clinical trials.
- To determine if 18F-FTT uptake correlates with PARP-1 protein expression in breast cancer tissue.
Main Methods
- Thirty women with breast cancer received 18F-FTT injections and underwent dynamic PET imaging.
- Kinetic analysis of 18F-FTT uptake was performed using blood-pool activity and radiometabolite corrections.
- Correlation between 18F-FTT uptake and PARP-1 protein expression was assessed in patient tissue and validated in mouse xenografts.
Main Results
- 18F-FTT pharmacokinetics were characterized by reversible binding models, but rapid metabolism was observed.
- Tumor 18F-FTT distribution volume ratios correlated significantly with tissue PARP-1 expression (P < 0.02).
- A static imaging protocol between 50-60 minutes post-injection showed close correspondence to dynamic imaging and PARP-1 expression.
Conclusions
- 18F-FTT uptake in vivo reflects PARP-1 expression in breast cancer.
- Quantification of 18F-FTT is influenced by radiometabolites, necessitating optimal imaging timing.
- A clinically practical static imaging protocol (45-55 min post-injection) can effectively quantify PARP-1 expression using 18F-FTT.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Radioactive Tracer: PET involves using biologically active molecules labeled with radioactive isotopes, known as tracers or radiotracers. The...